Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CA120528 | Other Identifier | NCI |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
This research study is evaluating a new method for determining stage and prognosis of individuals with malignant pleural mesothelioma.
The purpose of this research study is to test a new method for determining the stage and prognosis of patients with malignant pleural mesothelioma. Currently, it is not possible to accurately determine cancer stage prior to surgery or another treatment. This new method may allow doctors to better classify cancer stage and give a better estimate for prognosis prior to surgery or another treatment.
In this research study, the investigators would like to use biopsied tissue to study certain characteristics that will help test the new method for determining cancer stage and estimating prognosis.
In this research study, the investigators are...
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| MRiS | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| MPT Test | Other | molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pre-treatment Prognostic Algorithm Validation | The primary objective is to utilize a novel prognostic algorithm to predict the outcome of MPM patients. This algorithm includes 4 different tests: molecular, radiological, and blood based. It will be performed on 240 prospectively-collected samples. A score of 0-4 will be assigned to each patient and the data will be analyzed by a statistician | 4 years |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of Molecular Tests Base on RNA Expression | The secondary objective is to develop new molecular signatures for distinct clusters of mesothelioma samples grouped according to their gene expression. RNA expression data will be compared between one cluster and all the other clusters and using a variety of statistical and bioinformatics tools. Two-hundred sixteen MPM cases with available RNAseq data will be divided into training and test sets to develop and test potential signatures. The signatures that define each cluster with high sensitivity and specificity will then be tested using RTPCR in a cohort of 555 prospective-collected samples. |
Not provided
Inclusion Criteria:
All adult patients with a diagnosis of malignant pleural mesothelioma undergoing
Participants must be 18 years of age or older.
Exclusion Criteria:
-Any patient who is found to be unsuitable for
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Raphael Bueno, MD | Contact | 617-732-5690 | rbueno@partners.org |
| Name | Affiliation | Role |
|---|---|---|
| Raphael Bueno, MD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Recruiting | Boston | Massachusetts | 02215 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D008654 | Mesothelioma |
| ID | Term |
|---|---|
| D000236 | Adenoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| CLDN15/VIM Test | Other | molecular expression tests at the RNA level using approximately 7 or more genes with RTPCR, nanostring or similar platforms |
|
| 4 years |
| D018301 |
| Neoplasms, Mesothelial |